Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;43(11):1275-1279.
doi: 10.1002/cac2.12478. Epub 2023 Aug 16.

Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer

Yongzhan Nie #  1 , Xianchun Gao #  1 , Xiqiang Cai #  2 , Zhen Wu #  3 , Qiaoyi Liang  4 , Guobing Xu  5 , Na Liu  6 , Peng Gao  7 , Jingyu Deng  8 , Hongzhi Xu  9 , Zhanlong Shen  10 , Changqi Cao  5 , Fenrong Chen  6 , Nannan Zhang  1 , Yongxi Song  7 , Mingjun Sun  11 , Chengyin Liu  3 , Guangpeng Zhou  3 , Weili Han  1 , Jianhua Dou  1 , Huahong Xie  1 , Liping Yao  1 , Zhiguo Liu  1 , Gang Ji  1 , Xin Wang  2 , Qingchuan Zhao  1 , Lei Shang  12 , Daiming Fan  1 , Xiaoliang Han  3 , Jianlin Ren  9 , Han Liang  8 , Zhenning Wang  7 , Jinhai Wang  6 , Qi Wu  5 , Jun Yu  4 , Kaichun Wu  1 ; MAGIS Study Group
Affiliations

Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer

Yongzhan Nie et al. Cancer Commun (Lond). 2023 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Zhen Wu, Chengyin Liu, Dr. Guangpeng Zhou and Dr. Xiaoliang Han are current employees of BioChain (Beijing) Science & Technology, Inc., which has licensed the technology of the blood‐based SEPT9 assay from Epigenomics AG (Berlin, Germany). The other authors have no potential conflicts of interest to report.

Figures

FIGURE 1
FIGURE 1
Testing and validation of mSEPT9 and mRNF180 in the validation cohort. (A, B) Methylation levels of RNF180 and SEPT9 in the plasma by the disease status in the prospective validation cohort. Dot plots illustrating DNA methylation levels of subjects with gastric neoplastic lesions or non‐neoplastic disease (mRNF180 and mSEPT9, respectively) are shown; (C) ROC curve analysis of mSEPT9, mRNF180, and the RS9 panel in GA patients and controls; (D) Diagnostic performance of mSEPT9, mRNF180, and the RS9 panel in GA patients and controls. Abbreviations: AG, atrophic gastritis; AUC, area under the curve; Ct, threshold cycle; DE, diagnostic efficiency; GA, gastric adenocarcinoma; GP, gastric polyp; IM, intestinal metaplasia; NA, not available; Non‐AG, non‐atrophic gastritis; NPV: negative predictive value; PPV: positive predictive value.
See this image and copyright information in PMC

References

    1. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17(1):26‐33. - PubMed
    1. Feng F, Tian Y, Xu G, Liu Z, Liu S, Zheng G, et al. Diagnostic and prognostic value of CEA, CA19‐9, AFP and CA125 for early gastric cancer. BMC Cancer. 2017;17(1):737. - PMC - PubMed
    1. Ibrahim J, Peeters M, Van Camp G, Op de Beeck K. Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives. Eur J Cancer. 2023;178:91‐113. - PubMed
    1. Cheung KF, Lam CN, Wu K, Ng EK, Chong WW, Cheng AS, et al. Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer. Cancer. 2012;118(4):947‐59. - PubMed
    1. Han F, Sun LP, Liu S, Xu Q, Liang QY, Zhang Z, et al. Promoter methylation of RNF180 is associated with H.pylori infection and serves as a marker for gastric cancer and atrophic gastritis. Oncotarget. 2016;7(17):24800‐9. - PMC - PubMed

Publication types